Preoperative intramuscular testosterone and urethrocutaneous fistula formation after primary hypospadias repair.
Preoperative testosterone was not associated with increased urethrocutaneous fistula risk after hypospadias repair
Preoperative intramuscular testosterone and urethrocutaneous fistula formation after primary hypospadias repair.
Preoperative androgen stimulation is widely used before hypospadias repair to increase penile dimensions and optimise surgical conditions.
To evaluate the association between preoperative intramuscular testosterone therapy and urethrocutaneous fistula formation in children undergoing primary hypospadias repair.
Were divided into two groups: those who did not receive hormonal therapy (Group 1, n = 55) and those who received intramuscular testosterone enanthate (2 mg/kg administered 5 and 2 weeks before surgery; Group 2, n = 56).
similar fistula rates, testosterone did not raise the risk
Preoperative testosterone therapy was associated with significant increases in glans diameter and stretched penile length at the time of surgery.
The hormone-treated group had a significantly higher proportion of proximal hypospadias (p = 0.001), underwent more complex urethroplasty procedures, and had longer operative times (p = 0.007).
Postoperative edema and local inflammatory changes were more frequently observed in the hormone-treated group.
DISCUSSION: Despite greater baseline anatomical severity and operative complexity in the hormone-treated group, preoperative testosterone administration was not associated with an increased risk of urethrocutaneous fistula.
Selective preoperative intramuscular testosterone therapy was not associated with increased urethrocutaneous fistula risk and may be considered a reasonable adjunct in appropriately selected patients undergoing primary hypospadias repair.